US China Trade IP Agreement Phase 1-Pharmaceutical related IP issues

June 17th, 2020 | 10 AM EST – 11:30 AM EST | Zoom Webinar

Event Agenda


10:00-10:20

US-China Economic and Trade Agreement Phase 1:

What does it mean to US companies and IP attorneys?

Randall Rader, Former Chief Judge of US Federal Circuit of Patent Appeal court
Board of Directors, Trustee, UCIPF

 

10:20-11:20

Patent Linkage

Is China implementing a new linkage system as a result of the Phase 1 Agreement?

How is the new linkage system different from the prior voluntary system?

Jonathan Miao, Senior Partner, NTD Patent & Trademark Agency Limited, China

 

Has China implemented an orange book type system to identify approved pharmaceuticals which have patent protection?

Is it working to deter Chinese regulatory approval of infringing pharmaceuticals?

Benjamin Hsing, Partner, McguireWoods LLP

 

The Phase I Agreement does not provide a system of “artificial infringement” for linkage.  Can and should China implement a linkage system without “artificial infringement”?

Mark Cohen, Lecturer in Law, Distinguished
Senior Fellow, and Director at the University of California at Berkeley
Member of Advisory Board, UCIPF

 

11:20-11:30

Q&A

 

11:30-11:35

Closing remarks
Demi Wang, Founder, Chief Executive Officer

 

Thank you to our supporters!

Speakers


Randall Rader

Mark Cohen

Jonathan Miao

Benjamin Hsing

Demi Wang – Founder, Chief Executive Officer


June 17th, 2020

10 AM – 11:30 AM EST

Zoom Webinar

Reserve your seat

The numbers below include tickets for this event already in your cart. Clicking "Get Tickets" will allow you to edit any existing attendee information as well as change ticket quantities.
Professional
$ 150.00
Student
$ 100.00